


View Now | How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease







When: July 21, 2021, 12 p.m. ET

Case Study: Northstar Ambulatory Assessment as an outcome assessment in Duchenne muscular dystrophy

Presenters: Varun Aggarwal, PhD, Director, Statistical and Mathematical Medicine, Quantitative Medicine; Kevin Krudys, PhD, Office of Clinical Pharmacology, FDA

RDCA-DAP team: <u>Jeff Barrett</u>, PhD, FCP, Senior Vice President, RDCA-DAP Lead; Alexandre Bétourné, PhD, PharmD, Scientific Director, RDCA-DAP

View Now